Ark Bio Of China Bets On Untapped Pediatric Antiviral Market Where Few Have Succeeded
Founded five years ago, Shanghai-based Ark Bio sees big potential in the less crowded pediatric antiviral treatment market. Now the start-up is in Phase II development for its lead asset ziresovir for respiratory syncytial virus (RSV) infection, which was licensed from Roche.
You may also be interested in...
Chief executives of two antiviral and vaccine developers share with Scrip their development plans and projections as the death toll from the coronavirus outbreak reaches 900 with more cases being confirmed worldwide.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
Johnson & Johnson has written off a further $700m against the RSV asset that it obtained with its $1.75bn purchase of Alios.